Knight Therapeutics (GUD) Stock Price, News & Analysis

Company Overview

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

Key Stats

• Today's Range: C$9.20 to C$9.32
• 50-Day Range: C$9.14 to C$10.07
• 52-Week Range: C$5.66 to C$10.17
• Volume: 122,188 shs
• Average Volume: 98,691 shs
• Market Capitalization: C$915.52 million
• P/E Ratio: 62.13
• Dividend Yield: N/A
• Price Target: C$9.50
• Consensus Rating: Buy

Knight Therapeutics Stock Analysis - MarketRank™

Knight Therapeutics scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Knight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Knight Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Knight Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Knight Therapeutics is 62.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Knight Therapeutics is 62.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.27.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.

Price to Book Value per Share Ratio

Knight Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GUD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Knight Therapeutics does not currently pay a dividend.

Dividend Growth

Knight Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: N/A

News Sentiment

Knight Therapeutics has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Knight Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.77% of the stock of Knight Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/15/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: TSE:GUD
• CIK: N/A
• Web: www.gud-knight.com
• Phone: 514-484-4483
• Fax: N/A
• Employees: 725
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Knight Therapeutics: C$9.50
• High Price Target: C$9.50
• Low Price Target: C$9.50
• Potential Upside/Downside: +1.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.15
• Trailing P/E Ratio: 62.13
• Forward P/E Ratio: 92.32
• P/E Growth: -1013.5
• Net Income: -C$30.73 million
• Net Margins: 2.72%
• Pretax Margin: N/A
• Return on Equity: 1.91%
• Return on Assets: 0.51%

Debt

• Debt-to-Equity Ratio: 4.29
• Current Ratio: 2.28
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: C$547.31 million
• Price / Sales: 1.67
• Cash Flow: C$2.42 per share
• Price / Cash Flow: 3.85
• Book Value: C$8.13 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 98,232,000
• Free Float: N/A
• Market Cap: C$915.52 million
• Optionable: Not Optionable
• Beta: -0.19